FDA approves nasal drug delivery device for breakthrough treatment of depression

19 Mar 2019

Aptar Pharma’s Bidose liquid system is designed for local or systemic delivery of drugs.

Aptar Pharma's Bidose nasal spray device has been approved by the FDA for a breakthrough therapy in the field of depression. This marks the first FDA approval and US launch of a prescription drug using Aptar Pharma’s patented Bidose nasal spray delivery system.

FDA approves nasal drug delivery device for breakthrough treatment of depression
Photo: Courtesy of Aptar Pharma.

This approval again demonstrates Aptar Pharma’s expertise in developing patient-friendly drug delivery solutions for breakthrough medicines.

Patented Bidose Technology Platform

Aptar Pharma’s Bidose liquid system is designed for local or systemic delivery of drugs. As a robust, primeless, intuitive and easy-to-use device with 360° functionality and precise spray characteristics, the Bidose system provides accurate two-shot nasal drug delivery.

The Aptar Pharma Bidose and Unidose systems offer biotech and pharmaceutical companies effective and reliable intra-nasal delivery platforms for a variety of medicines including potential life-saving treatments and treatments of severe conditions.

This nasal product platform can enhance brand image via an elegant and intuitive design while limiting the volume of drug accessible to patients. The devices can also integrate wireless connectivity technologies.

Accelerated Development Support via Aptar Pharma Services

This breakthrough therapy approval is an example of a Combination Product, and benefited from Aptar Pharma’s Services offering, a comprehensive portfolio of stage-specific packages designed to proactively address regulatory needs to accelerate approval.

Leveraging its extensive value-adding capabilities including lab and analytical services, proven regulatory expertise - with dedicated Regulatory Affairs experts and fast approval data packages - and customized drug delivery solutions, Aptar Pharma’s Services can enable an expedited approval and launch in the competitive pharmaceutical space.

“We are pleased that Aptar Pharma’s Bidose nasal delivery device has been approved by the FDA for this breakthrough therapy in the field of depression,” explained Gael Touya, President, Aptar Pharma. “This project marks close to a 10-year customer collaboration and once again demonstrates Aptar Pharma’s ability to develop and launch complex drug delivery systems worldwide.”

Read More

Related news

New HCP Kit for automated impurity analysis of biotherapeutics

New HCP Kit for automated impurity analysis of biotherapeutics

21 Jun 2019

Ready-to-use immunoassay kit increases analytical output and productivity in bioprocess workflows.

Read more 
Sanofi and Google to develop new healthcare Innovation Lab

Sanofi and Google to develop new healthcare Innovation Lab

20 Jun 2019

Collaboration aims to change how Sanofi develops new treatments and will focus on to better understand patients and diseases, to increase Sanofi’s operational efficiency, and to improve the experience of Sanofi’s patients and customers.

Read more 
Catalent to purchase BMS manufacturing facility

Catalent to purchase BMS manufacturing facility

19 Jun 2019

Customers to have access to state-of-the-art sterile biologics fill/finish and oral solids manufacturing and packaging platforms.

Read more 
Inaugural Bio Integrates conference highlights industry's inefficiency in developing products

Inaugural Bio Integrates conference highlights industry's inefficiency in developing products

18 Jun 2019

Industry leaders give voice to issues and trends shaping the biotech sector, including the importance of collaboration.

Read more 
Colorcon launches Opadry Enteric for use with hydro-alcoholic media

Colorcon launches Opadry Enteric for use with hydro-alcoholic media

17 Jun 2019

A fully formulated one-step system providing simple preparation and ease-of-use for film coating.

Read more 
SenzaGen granted its first patent for GARD potency biomarker test

SenzaGen granted its first patent for GARD potency biomarker test

16 Jun 2019

Company can now offer an animal-free test method to quantify the strength of an allergenic effect.

Read more 
Affordable measles and rubella vaccines using NevoLine manufacturing platform

Affordable measles and rubella vaccines using NevoLine manufacturing platform

14 Jun 2019

Univercells' propriety bioproduction platform has already proven success.

Read more 
Leaf Expression Systems launches first line of Hypertrans research products

Leaf Expression Systems launches first line of Hypertrans research products

13 Jun 2019

Plant-expression deal for difficult to produce proteins, vaccines, metabolites and natural proteins.

Read more 
Clinical supply milestone reached for triple-negative breast cancer treatment

Clinical supply milestone reached for triple-negative breast cancer treatment

12 Jun 2019

PhoenixMD and WuXi STA have produced a multikilogram drug supply for PMD-026 under GMP manufacturing practices.

Read more 
Combining IT and OT software to solve manufacturing’s most frequent challenges

Combining IT and OT software to solve manufacturing’s most frequent challenges

11 Jun 2019

PTC and Rockwell Automation combine technologies to accelerate customers’ digital transformation initiatives.

Read more